{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-03-18",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Lumberton",
      "state": "NJ",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "84583",
      "recalling_firm": "AAA Pharmaceutical, Inc.",
      "address_1": "681 Main St",
      "address_2": "N/A",
      "postal_code": "08048-5013",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Product was distributed to one consignee who may have distributed the product further to their retail stores.",
      "recall_number": "D-0646-2020",
      "product_description": "Ranitidine 150 mg tablets, 130 count bottles, NDC 37808-196-04.",
      "product_quantity": "31,536 (130-count bottles)",
      "reason_for_recall": "CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API",
      "recall_initiation_date": "20191226",
      "center_classification_date": "20200106",
      "termination_date": "20210310",
      "report_date": "20200115",
      "code_info": "P134457, Sept 2020  P135156, Aug 2020  P135156, Aug 2020  P135243, Aug 2020  P135877, Sept 2020  P136145, Aug 2020  P136146, Sept 2020  P136623, April 2021  P136728, April, 2021  P136994, April, 2021  P137348, April, 2021  P137423, April, 2021  P137499, April, 2021"
    }
  ]
}